This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI (IMPLANT2)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
ObsEva SA Identifier:
First received: March 6, 2017
Last updated: September 6, 2017
Last verified: September 2017
The primary objective of this study is to confirm the efficacy of a single oral 900mg dose of nolasiban to increase the ongoing clinical pregnancy rate at 10 weeks post embryo transfer (ET) day.

Condition Intervention Phase
Infertility Drug: Nolasiban 900mg Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Double Blind
Primary Purpose: Treatment
Official Title: A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Oral Administration of Nolasiban to Improve Pregnancy Rates Following IVF or ICSI in Day 3 and Day 5 Fresh Embryo Transfer Cycles

Further study details as provided by ObsEva SA:

Primary Outcome Measures:
  • Intra-uterine pregnancy with fetal heart beat at 10 weeks [ Time Frame: 10 weeks post ET day ]
    Intra-uterine pregnancy with fetal heart beat at 10 weeks post embryo transfer day

Secondary Outcome Measures:
  • Live birth [ Time Frame: Up to 42 weeks of gestation ]
    Live birth after 24 weeks of gestation

  • Miscarriage [ Time Frame: From 6 weeks post ET to 24 weeks gestation ]
    Any clinical pregnancy that does not result in a live birth prior 24 weeks

  • Intra-uterine pregnancy at 6 weeks [ Time Frame: 6 weeks post ET ]
    Intra-uterine pregnancy with fetal heart beat at 6 weeks post ET day

  • Positive blood pregnancy test [ Time Frame: 14 days post OPU ]
    Positive blood pregnancy test at 14 days post oocyte pick-up (OPU)

Other Outcome Measures:
  • Adverse events [ Time Frame: Through study completion, up to 11 months ]
    Frequency and severity of treatment emergent adverse events

  • Neonatal assessments [ Time Frame: Birth of infant until 28 days ]
    Incidence of any malformation or any significant morbidity during the neonatal period

  • ASQ-3 [ Time Frame: 6 months after term ]
    Ages and Stages Questionnaire-3 (ASQ-3) domain score(s) at 6 months, adjusted for gestational age at birth

Estimated Enrollment: 760
Actual Study Start Date: March 6, 2017
Estimated Study Completion Date: April 2019
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nolasiban 900 mg Drug: Nolasiban 900mg
Nolasiban dispersible tablets for single oral administration
Placebo Comparator: Placebo Drug: Placebo
Placebo dispersible tablets for single oral administration

Detailed Description:
The study is a prospective, randomized, parallel group, double-blind, placebo-controlled study to confirm the efficacy and the safety of the oxytocin receptor antagonist, nolasiban, in 760 women undergoing fresh embryo transfer following in vitro fertilisation (IVF) or intra-cytoplasmic sperm injection (ICSI).

Ages Eligible for Study:   18 Years to 36 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Indicated for IVF/ICSI in the context of assisted reproductive technology (ART)
  • Follow a gonadotropin releasing hormone (GnRH) antagonist protocol, single injection of human chorionic gonadotropin (hCG) for triggering final follicular maturation and luteal phase support with vaginal micronized progesterone.
  • Single, fresh D3 or D5 embryo transfer

Key Exclusion Criteria:

  • Frozen-thawed embryo transfer
  • More than 20 oocytes in the current controlled ovarian hyperstimulation (COH) cycle
  • Serum P4 greater than 1.5 ng/mL on the day of hCG administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03081208

  Show 42 Study Locations
Sponsors and Collaborators
ObsEva SA
Study Director: ObsEva SA Geneva
  More Information

Responsible Party: ObsEva SA Identifier: NCT03081208     History of Changes
Other Study ID Numbers: 16-OBE001-005
Study First Received: March 6, 2017
Last Updated: September 6, 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by ObsEva SA:

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female processed this record on September 21, 2017